Potential Mylan (MYL)/Upjohn (PFE) Merger a 'Goldilocks Scenario' - Mizuho
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St indexes eye weekly losses; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
UPDATE: Pfizer (PFE) Tops Q2 EPS by 5c, Revenues Miss; Lowers FY19 EPS/Revenue Guidance
July 29, 2019 6:51 AM EDT(Updated - July 29, 2019 6:54 AM EDT)
Pfizer (NYSE: PFE) reported Q2 EPS of $0.80, $0.05 better than the analyst estimate of $0.75. Revenue for the quarter came in at $13.26 billion versus the consensus estimate of $13.4 billion.
Second-Quarter 2019 Revenues of $13.3 Billion, Reflecting 2% Operational Growth Driven by 6% Operational Growth from Pfizer Biopharmaceuticals GroupSecond-Quarter 2019 Reported Diluted EPS(1) of $0.89, Adjusted Diluted EPS(2) of $0.80Updated 2019 Financial Guidance Primarily to Reflect the Anticipated August 1, 2019 Formation of the Consumer Healthcare Joint Venture with GlaxoSmithKline plc(3) and the Anticipated Near-Term Completion of the Array BioPharma Inc. AcquisitionAnnounces Reverse Morris Trust... MoreMylan (MYL) in Talks to Merge with Pfizer's (PFE) Off-Patent Drug Business - Reports
July 28, 2019 11:42 AM EDTMylan (NASDAQ: MYL) shares will be on watch Monday amid reports the company is in talks to merge with Pfizer's (NYSE: PFE) off-patent drug unit in a stock deal.
Mylan shareholders would receive a little more than 40% of... More
